Huntington's Disease News and Research RSS Feed - Huntington's Disease News and Research

Huntington's disease (HD) results from genetically programmed degeneration of brain cells, called neurons, in certain areas of the brain. This degeneration causes uncontrolled movements, loss of intellectual faculties, and emotional disturbance. HD is a familial disease, passed from parent to child through a mutation in the normal gene. Each child of an HD parent has a 50-50 chance of inheriting the HD gene. If a child does not inherit the HD gene, he or she will not develop the disease and cannot pass it to subsequent generations. A person who inherits the HD gene will sooner or later develop the disease. Whether one child inherits the gene has no bearing on whether others will or will not inherit the gene. Some early symptoms of HD are mood swings, depression, irritability or trouble driving, learning new things, remembering a fact, or making a decision. As the disease progresses, concentration on intellectual tasks becomes increasingly difficult and the patient may have difficulty feeding himself or herself and swallowing. The rate of disease progression and the age of onset vary from person to person. A genetic test, coupled with a complete medical history and neurological and laboratory tests, helps physicians diagnose HD. Presymptomic testing is available for individuals who are at risk for carrying the HD gene. In 1 to 3 percent of individuals with HD, no family history of HD can be found.
Research findings may pave way to new treatment for Alzheimer's disease in humans

Research findings may pave way to new treatment for Alzheimer's disease in humans

A drug developed by scientists at the Salk Institute for Biological Studies, known as J147, reverses memory deficits and slows Alzheimer's disease in aged mice following short-term treatment. [More]
TRACK-HD study: A set of tests could help identify progression of Huntington's disease

TRACK-HD study: A set of tests could help identify progression of Huntington's disease

Scientists have identified a set of tests that could help identify whether and how Huntington's disease is progressing in groups of people who are not yet showing symptoms. [More]
Study: Melatonin delays symptom onset, reduces mortality in mouse model of ALS

Study: Melatonin delays symptom onset, reduces mortality in mouse model of ALS

Melatonin injections delayed symptom onset and reduced mortality in a mouse model of the neurodegenerative condition amyotrophic lateral sclerosis, or Lou Gehrig's disease, according to a new study by researchers at the University of Pittsburgh School of Medicine. [More]
Investigational treatment for ALS passes early phase clinical trial for safety

Investigational treatment for ALS passes early phase clinical trial for safety

An investigational treatment for an inherited form of Lou Gehrig's disease has passed an early phase clinical trial for safety, researchers at Washington University School of Medicine in St. Louis and Massachusetts General Hospital report. [More]
Animal models of Huntington's disease allow better insights into disease's genetics

Animal models of Huntington's disease allow better insights into disease's genetics

Scientific progress in Huntington's disease (HD) relies upon the availability of appropriate animal models that enable insights into the disease's genetics and/or pathophysiology. [More]
Ceregene announces top-line data from CERE-12 Phase 2b clinical study for Parkinson's disease

Ceregene announces top-line data from CERE-12 Phase 2b clinical study for Parkinson's disease

Ceregene, Inc. today announced the top-line data from its double-blind, randomized, controlled Phase 2b clinical study of CERE-120 (AAV-neurturin), a gene therapy product designed to deliver the neurotrophic factor neurturin, for Parkinson's disease. [More]
Tacere Therapeutics submits TT-034 clinical trial application to Recombinant DNA Advisory Committee

Tacere Therapeutics submits TT-034 clinical trial application to Recombinant DNA Advisory Committee

RNAi-based therapeutics company Benitec Biopharma Limited today announced that the company's wholly owned US subsidiary, Tacere Therapeutics Inc., has submitted an application to the US National Institutes of Health's Recombinant DNA Advisory Committee. [More]
Benitec to conduct phase I/II clinical trial of TT-034 in patients with HCV in UCSD site

Benitec to conduct phase I/II clinical trial of TT-034 in patients with HCV in UCSD site

RNAi-based therapeutics company Benitec Biopharma Limited today announced the selection of the University of California, San Diego, Health Sciences as the second site for its upcoming phase I/II first-in-man trial for TT-034 in Hepatitis C infections. [More]
Junk DNA plays important role in brain development

Junk DNA plays important role in brain development

Specific DNA once dismissed as junk plays an important role in brain development and might be involved in several devastating neurological diseases, UC San Francisco scientists have found. [More]
NCRI, Prize4Life recognized with Bio-IT World's Best Practices Award for creating PRO-ACT platform

NCRI, Prize4Life recognized with Bio-IT World's Best Practices Award for creating PRO-ACT platform

The Massachusetts General Hospital Neurological Clinical Research Institute and Prize4Life, a nonprofit organization whose mission is to accelerate the discovery of treatments and a cure for amyotrophic lateral sclerosis, received a Best Practices Award at the 2013 Bio-IT World Conference & Expo. [More]
Roche, Isis Pharmaceuticals to develop neurodegenerative therapeutics for Huntington's disease

Roche, Isis Pharmaceuticals to develop neurodegenerative therapeutics for Huntington's disease

Roche and Isis Pharmaceuticals, Inc today announced that they have formed an alliance to develop treatments for Huntington's disease based on Isis' antisense oligonucleotide technology. [More]
Clinical trial signals new era in treatment of neurodegererative disorders

Clinical trial signals new era in treatment of neurodegererative disorders

The initial clinical trial of a novel approach to treating amyotrophic lateral sclerosis - blocking production of a mutant protein that causes an inherited form of the progressive neurodegererative disease - may be a first step towards a new era in the treatment of such disorders. [More]
Johns Hopkins scientists identify role of central nervous system cell in development of ALS

Johns Hopkins scientists identify role of central nervous system cell in development of ALS

Johns Hopkins scientists say they have evidence from animal studies that a type of central nervous system cell other than motor neurons plays a fundamental role in the development of amyotrophic lateral sclerosis, a fatal degenerative disease. [More]
Molecular biologist hopes to learn why degenerative disorder affects specific brain cells

Molecular biologist hopes to learn why degenerative disorder affects specific brain cells

Dr. Santosh D'Mello, professor of molecular and cell biology at the University of Texas at Dallas, has received a federal grant for research that may shed light on why and how specific brain cells are affected by Huntington's disease, a devastating, degenerative brain disorder. [More]

USF, Saneron receive patent for transplantation method using umbilical cord blood cells

Researchers at Saneron CCEL Therapeutics and the University of South Florida have received a patent relating to a method for obtaining and using umbilical cord blood cells from a donor or patient to provide neural cells for transplantation aimed at repairing a variety of neurodegenerative diseases of the brain and spinal cord, such as Parkinson's disease, Huntington's disease, multiple sclerosis, Alzheimer's disease as well as brain and spinal cord injury. [More]
Researchers discover how LRRK2 mutations in familial Parkinson's damage brain cells

Researchers discover how LRRK2 mutations in familial Parkinson's damage brain cells

Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered how the most common genetic mutations in familial Parkinson's disease damage brain cells. [More]

DDR may help decrease cognitive and physical effects of multiple sclerosis

Studies have shown that the popular video game, Dance Dance Revolution (DDR), which requires players to coordinate their movements to the beat of music, may help improve balance and mobility in certain patient populations. [More]
MID1 complex binds with messenger RNA and controls synthesis of defective Huntingtin

MID1 complex binds with messenger RNA and controls synthesis of defective Huntingtin

Huntington's disease, also known as Huntington's chorea, is a hereditary brain disease causing movement disorders and dementia. In Germany, there are about 8,000 patients affected by Huntington's disease, with several hundred new cases arising every year. The disease usually manifests between the ages of 35 and 50. [More]

Symptoms poor guide to testing for juvenile Huntington disease

The onset or presentation of specific clinical features that are typical of juvenile Huntington’s Disease (JHD) do not help physicians to diagnose the condition without genetic testing. [More]

TP PCR methodology may help streamline genetic testing for Huntington's

A new test may help to streamline genetic testing for Huntington Disease (HD) by generating accurate results, avoiding unnecessary additional testing, and improving turnaround time. [More]